Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.

Literature DB >> 3034145

In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.

Abstract

The in vitro activity of LY146032, a novel cyclic lipopeptide antibiotic, was tested against different gram-positive clinical isolates. The activity of LY146032 was clearly higher than that of vancomycin against all isolates tested. However, in some instances rifampin and imipenem showed higher activity than did LY146032.

Entities: Chemical

Mesh：

Substances：

Year: 1987 PMID： 3034145 PMCID： PMC174751 DOI： 10.1128/AAC.31.3.455

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

5 in total

1. Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci.

Authors: D S Davenport; R M Massanari; M A Pfaller; M J Bale; S A Streed; W J Hierholzer
Journal: J Infect Dis Date: 1986-02 Impact factor: 5.226

2. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors: G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

3. Aminoglycoside resistance among blood culture isolates.

Authors: P Huovinen; P Grönroos; E Herva; M L Katila; M L Klossner; O V Renkonen; P Toivanen
Journal: J Clin Microbiol Date: 1984-07 Impact factor: 5.948

4. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors: J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal: N Engl J Med Date: 1978-03-09 Impact factor: 91.245

5. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces.

Authors: G D Christensen; W A Simpson; A L Bisno; E H Beachey
Journal: Infect Immun Date: 1982-07 Impact factor: 3.441

5 in total

12 in total

1. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

Authors: K Vance-Bryan; T A Larson; J C Rotschafer; J P Toscano
Journal: Antimicrob Agents Chemother Date: 1992-10 Impact factor: 5.191

2. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin.

Authors: Q N Luu; T B Buxton; D R Nelson; J P Rissing
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-06 Impact factor: 3.267

3. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

Authors: A Louie; P Kaw; W Liu; N Jumbe; M H Miller; G L Drusano
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

4. Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits.

Authors: C S Haworth; M W Sobieski; W M Scheld; T S Park
Journal: Antimicrob Agents Chemother Date: 1990-02 Impact factor: 5.191

5. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.

Authors: A W Chow; N Cheng
Journal: Antimicrob Agents Chemother Date: 1988-05 Impact factor: 5.191

6. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.

Authors: C A Wood; H C Finkbeiner; S J Kohlhepp; P W Kohnen; D N Gilbert
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

7. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191